Understanding CBS: Potential Drug Targets and Biomarker for Diseases

Target Name: CBS

NCBI ID: G875

Content of Review Report on CBS Target / Biomarker

CBS

Understanding CBS: Potential Drug Targets and Biomarker for Diseases

CBS (CBS variant 4) is a protein that is expressed in various tissues throughout the body. It is a key regulator of cell division and has been implicated in many diseases, including cancer. In recent years, researchers have been interested in studying the potential drug targets of CBS in order to develop new treatments for various diseases.

One of the main challenges in studying CBS as a drug target is its complex structure. CBS is a transmembrane protein that is composed of multiple domains, including an extracellular domain, a transmembrane domain, and an intracellular domain. The transmembrane domain is responsible for the protein's ability to interact with other cells and molecules, and is a key region for drug targeting.

To study the potential drug targets of CBS, researchers have used a variety of techniques, including yeast two-hybrid, protein fragment complementation, and mass spectrometry. These studies have identified several potential drug targets in CBS, including the N-terminal and C-terminal domains, as well as the intracellular domain.

One of the most promising potential drug targets is the N-terminal domain. This domain is involved in the regulation of cell division and has been implicated in the development of many diseases, including cancer. Researchers have identified several potential small molecules that can interact with this domain and are currently in the process of testing these compounds as potential drugs.

Another promising potential drug target is the C-terminal domain. This domain is involved in the regulation of cell adhesion and has also been implicated in the development of many diseases, including cancer. Researchers have identified several potential small molecules that can interact with this domain and are currently in the process of testing these compounds as potential drugs.

In addition to these potential drug targets, CBS has also been identified as a potential biomarker for several diseases, including cancer. This is because the expression of CBS is often reduced in cancer cells, and researchers have identified that compounds that can increase the expression of CBS in cancer cells could be useful as drugs for cancer treatment.

Overall, the study of CBS as a drug target is an promising area of research with the potential to lead to new treatments for a variety of diseases. While further studies are needed to fully understand the complex structure and function of CBS, researchers are excited about the potential of this protein as a drug target and are actively working to develop new compounds that can interact with its various domains.

Protein Name: Cystathionine Beta-synthase

The "CBS Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CBS comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets